The article on therapeutic cloning ("Will Britain buy a therapeutic cell?", THES, February 25) gave a good account of the debate. But there were two errors. First, the Roslin Institute remains very much in the public sector; it is one of our spin-off firms, Roslin BioMed, that has been acquired by Geron. Second, we are based in Edinburgh, not Aberdeen.
H. D. Griffin Assistant director (science)Roslin Institute, Edinburgh
Register to continue
Why register?
- Registration is free and only takes a moment
- Once registered, you can read 3 articles a month
- Sign up for our newsletter
Subscribe
Or subscribe for unlimited access to:
- Unlimited access to news, views, insights & reviews
- Digital editions
- Digital access to THE’s university and college rankings analysis
Already registered or a current subscriber? Login